GANX - Gain Therapeutics, Inc. Stock Price, Fair Value and News

2.59USD-0.10 (-3.72%)Market Closed

Market Summary

USD2.59-0.10

Market Closed

-3.72%

GANX Stock Price

View Fullscreen

GANX RSI Chart

GANX Valuation

Market Cap

46.8M

Price/Earnings (Trailing)

-2.21

Price/Sales (Trailing)

847.31

EV/EBITDA

-1.78

Price/Free Cashflow

-2.56

GANX Price/Sales (Trailing)

GANX Profitability

EBT Margin

-38169.58%

Return on Equity

-244.67%

Return on Assets

-145.05%

Free Cashflow Yield

-39%

GANX Fundamentals

GANX Revenue

Revenue (TTM)

55.2K

GANX Earnings

Earnings (TTM)

-21.1M

Earnings Growth (Yr)

21.86%

Earnings Growth (Qtr)

15.02%

Breaking Down GANX Revenue

Last 7 days

3.2%

Last 30 days

-18.5%

Last 90 days

-46.3%

Trailing 12 Months

-45.8%

How does GANX drawdown profile look like?

GANX Financial Health

Current Ratio

2.77

Debt/Equity

0.05

Debt/Cashflow

-45.95

GANX Investor Care

Shares Dilution (1Y)

46.42%

Diluted EPS (TTM)

-1.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	150.3K	55.2K	55.2K	55.2K
2022	204.7K	210.7K	183.3K	140.1K
2021	27.5K	110.3K	130.9K	165.0K
2020	0	0	0	28.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Gain Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	riley jeffrey scott	bought	115,770	3.859	30,000	-
Mar 26, 2024	alder matthias	sold (taxes)	-24,705	4.06	-6,085	chief executive officer
Mar 26, 2024	alder matthias	acquired	-	-	20,212	chief executive officer
Dec 21, 2023	alder matthias	sold	-506	2.46	-206	chief executive officer
Dec 20, 2023	alder matthias	acquired	-	-	637	chief executive officer
Dec 07, 2023	alder matthias	sold	-4,550	2.5	-1,820	chief executive officer
Oct 01, 2023	alder matthias	acquired	-	-	825	chief executive officer
Sep 20, 2023	richman eric i	acquired	-	-	54,900	-
Sep 20, 2023	alder matthias	acquired	-	-	2,550	chief executive officer
Jul 01, 2023	alder matthias	acquired	-	-	3,300	chief executive officer

Which funds bought or sold GANX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Creekmur Asset Management LLC	unchanged	-	2,242	16,739	0.01%
May 15, 2024	Royal Bank of Canada	added	24.1	283,000	937,000	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-93.54	-197,591	15,921	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-34.92	-37,417	113,100	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	247	125,774	167,448	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	reduced	-38.35	-54,656	135,041	0.01%
May 15, 2024	DME Capital Management, LP	new	-	2,134,310	2,134,310	0.10%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-5.31	1,491	17,463	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	12,724	12,724	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	1,414	10,556	-%

Are Funds Buying or Selling GANX?

Are funds buying GANX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GANX

No. of Funds

Recent SEC filings of Gain Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 08, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	3	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading

Peers (Alternatives to Gain Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Gain Therapeutics, Inc. News

Latest updates

Gain Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-	-	-	-	55,180	-	-	95,102	45,006	43,208	27,345	89,173	5,269	9,139	6,696	6,373	6,673
Operating Expenses	-9.8%	4,407,230	4,885,005	7,731,114	5,284,964	4,561,199	4,750,984	5,271,487	3,333,483	3,251,977	4,663,270	3,603,736	2,472,184	1,624,774	825,785	538,838	518,933
S&GA Expenses	-19.2%	2,033,247	2,517,523	3,743,171	2,493,759	2,287,357	2,786,200	2,689,263	1,777,043	1,779,504	2,186,531	1,810,228	1,050,675	649,162	398,320	99,970	101,674
R&D Expenses	0.3%	2,373,983	2,367,482	3,987,943	2,791,205	2,273,842	1,964,784	2,582,224	1,556,440	1,472,473	2,476,739	1,793,508	1,421,509	975,612	427,465	438,868	417,259
EBITDA Margin	-0.8%	-391	-388	-385	-124	-121	-86.55	-76.58	-71.71	-83.99	-93.82	-76.40	-	-	-	-	-
Interest Expenses	0.3%	106,270	106,000	129,929	152,035	163,777	153,332	59,899	-1,651	267	4,918	5,901	1,408	6,895	7.00	-1,517	-1,747
Income Taxes	-32.4%	14,502	21,456	26,589	16,728	78,105	4,048	9,146	1,677	-8,244	5,114	3,660	3,479	-1,368	885	4,523	1,347
Earnings Before Taxes	-0.3%	-4,709,467	-4,696,807	-7,661,380	-5,120,591	-4,596,361	-4,554,161	-5,076,274	-3,270,966	-3,228,177	-4,658,419	-3,553,033	-2,446,968	-1,657,049	-793,486	-538,839	-582,921
EBT Margin	-0.5%	-402	-400	-397	-128	-124	-87.99	-77.06	-71.85	-84.16	-94.06	-76.63	-	-	-	-	-
Net Income	-0.1%	-4,723,969	-4,718,263	-7,687,969	-5,137,319	-4,674,466	-4,558,209	-5,085,420	-3,272,643	-3,219,933	-4,663,533	-3,556,693	-2,450,447	-1,655,681	-794,371	-543,362	-584,268
Net Income Margin	-0.2%	-403	-402	-399	-129	-125	-88.02	-77.10	-71.86	-84.19	-94.15	-76.69	-	-	-	-	-
Free Cashflow	-40.7%	-5,660,379	-4,023,894	-5,078,543	-4,274,594	-3,961,792	-3,346,255	-5,095,610	-2,455,216	-4,157,463	-2,224,461	-3,239,563	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-21.7%	14,577	18,609	14,097	18,261	21,323	24,099	28,326	31,890	37,599	38,985	42,562	45,353	48,041	9,604
Current Assets	-22.0%	13,863	17,779	13,242	17,308	19,322	21,091	24,349	25,833	36,392	37,722	41,555	44,335	47,384	8,988
Cash Equivalents	-9.5%	10,673	11,795	4,273	6,320	5,988	7,312	10,909	14,336	34,369	36,912	41,015	43,205	46,636	7,504
Net PPE	-11.2%	112	126	127	139	145	144	137	139	107	106	103	75.00	55.00	30.00
Liabilities	-1.6%	5,935	6,031	6,767	7,168	6,184	5,220	5,663	4,873	5,771	4,168	-	-	-	3,402
Current Liabilities	1.1%	5,004	4,950	5,763	5,588	5,155	4,125	4,332	3,410	4,217	2,553	3,577	2,451	2,327	2,115
Long Term Debt	-11.6%	397	449	435	467	478	495	484	542	561	590	620	647	678	716
LT Debt, Current	-6.7%	111	119	109	112	109	108	101	84.00	87.00	104	87.00	65.00	44.00	23.00
LT Debt, Non Current	-100.0%	-	449	435	467	478	495	484	542	561	590	620	647	678	716
Shareholder's Equity	-31.3%	8,642	12,578	7,331	11,093	15,139	18,880	22,663	27,017	31,828	34,818	37,545	41,389	44,464	6,202
Retained Earnings	-57.8%	-60,783	-38,516	-	-	-38,516	-20,925	-20,925	-20,925	-20,925	-7,034	-7,034	-7,034	-7,034	-3,457
Additional Paid-In Capital	0.4%	73,416	73,113	63,299	62,299	58,695	57,359	56,800	56,445	56,139	55,832	55,362	54,594	54,105	13,389
Shares Outstanding	11.3%	18,041	16,207	12,783	12,632	12,087	11,883	11,883	11,883	11,883	11,883	9,587	11,876	-	-
Float	-	-	-	-	56,600	-	-	-	38,800	-	-	-	118,700	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	36.6%	-3,586	-5,660	-3,966	-5,021	-4,217	-3,904	-3,289	-5,051	-2,447	-4,146	-2,192	-3,217	-2,809	-1,308	-755	-424	-752
Share Based Compensation	-65.7%	190	555	907	1,231	565	559	356	306	307	286	251	192	111	-	-	-	-
Cashflow From Investing	-3.9%	3,019	3,142	1,929	3,045	2,107	134	-11.41	-14,889	-7.82	-11.10	-32.12	-22.50	-28.49	-14.55	-1.42	38*	-4.90
Cashflow From Financing	-101.5%	-145	9,561	134	2,197	749	-21.58	-20.58	1.00	-37.97	-9.73	-	-213	41,990	-440	9,545	-10.55	1,393

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GANX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Collaboration revenues		$ 55,180
Total revenues		55,180
Operating expenses:
Research and development	$ (2,506,906)	(2,791,205)
General and administrative	(1,870,794)	(2,493,759)
Total operating expenses	(4,377,700)	(5,284,964)
Loss from operations	(4,377,700)	(5,229,784)
Other income/(expense):
Interest income, net	115,303	152,035
Foreign exchange gain/(loss), net	268,077	(42,842)
Loss before income tax	(3,994,320)	(5,120,591)
Income tax	(19,874)	(16,728)
Net loss	$ (4,014,194)	$ (5,137,319)
Net loss per shares:
Net loss per share attributable to common stockholders - Basic	$ (0.22)	$ (0.43)
Net loss per share attributable to common stockholders - Diluted	$ (0.22)	$ (0.43)
Weighted average common shares - Basic	17,978,951	11,935,081
Weighted average common shares - Diluted	17,978,951	11,935,081

GANX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,641,087	$ 11,794,949
Marketable securities - current	2,019,414	4,999,704
Tax credits	249,133	242,577
Prepaid expenses and other current assets	952,889	741,638
Total current assets	13,862,523	17,778,868
Non-current assets:
Property and equipment, net	111,909	125,962
Internal-use software	169,249	193,375
Operating lease - right of use assets	384,146	459,215
Restricted cash	31,744	34,021
Long-term deposits and other non-current assets	17,613	17,890
Total non-current assets	714,661	830,463
Total assets	14,577,184	18,609,331
Current liabilities:
Accounts payable	1,405,154	1,318,965
Operating lease liability - current	204,569	229,693
Other current liabilities	2,368,806	2,160,366
Deferred income - current	914,759	1,122,138
Loans - current	110,848	118,797
Total current liabilities	5,004,136	4,949,959
Non-current liabilities:
Defined benefit pension plan	292,486	307,454
Operating lease liability - non-current	177,365	229,855
Deferred income - non-current	64,300	94,786
Loans - non-current	396,836	449,053
Total non-current liabilities	930,987	1,081,148
Total liabilities	5,935,123	6,031,107
Stockholders' equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of March 31, 2024 and December 31, 2023.	0	0
Common stock, $0.0001 par value: 50,000,000 shares authorized; 18,041,231 issued and outstanding as of March 31, 2024; 16,206,680 issued and outstanding as of December 31, 2023.	1,805	1,621
Additional paid-in capital	73,416,304	73,113,079
Accumulated other comprehensive income	21,863	247,241
Accumulated deficit	(60,783,717)	(38,516,197)
Loss for the period	(4,014,194)	(22,267,520)
Total stockholders' equity	8,642,061	12,578,224
Total liabilities and stockholders' equity	$ 14,577,184	$ 18,609,331

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

CEO	Mr. Matthias Alder LIC. IUR., LL.M.
WEBSITE	gaintherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	28

Gain Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Gain Therapeutics, Inc.? What does GANX stand for in stocks?

GANX is the stock ticker symbol of Gain Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gain Therapeutics, Inc. (GANX)?

As of Fri May 17 2024, market cap of Gain Therapeutics, Inc. is 46.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GANX stock?

You can check GANX's fair value in chart for subscribers.

What is the fair value of GANX stock?

You can check GANX's fair value in chart for subscribers. The fair value of Gain Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gain Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GANX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gain Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GANX is over valued or under valued. Whether Gain Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Gain Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GANX.

What is Gain Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GANX's PE ratio (Price to Earnings) is -2.21 and Price to Sales (PS) ratio is 847.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GANX PE ratio will change depending on the future growth rate expectations of investors.